Four inputs set the figure. The acquisition cost of the molecule. Whether the product is an approved drug carrying a published list price or a compounded preparation that has none. The dispensing pharmacy’s own pricing. And the services wrapped around the medication. On a subscription platform the fourth input is often the largest, which is why the number tracks the program more than the drug.
Written by Dr. Neil Paulvin, DO, Family Medicine
List price, net price, and cash price are three separate numbers
An approved brand-name drug has a manufacturer list price, the figure quoted in headlines and paid by almost nobody. Below it sits a net price after rebates negotiated with plan intermediaries, which is confidential. Below or beside that sits a cash price, the amount a patient without coverage is charged at the counter.
Generics work differently. Once several manufacturers make the same molecule, competition collapses the spread, and the cash price becomes the operative number for most buyers. Generic products have to match the reference drug on active ingredient, strength, dosage form, and performance, which is what makes them interchangeable enough for price to be the deciding factor.
None of those three numbers is what a telehealth platform quotes. A subscription figure is a retail price for a package, set by the seller against its own costs and its competitors, and it moves for commercial reasons rather than because the underlying drug cost changed.
Compounded preparations have no list price at all
Compounded drugs are made to order under specific statutory conditions rather than manufactured against an approved application, and federal compounding law sets out what pharmacies and outsourcing facilities may prepare and when. There is no manufacturer, no published list price, and no rebate chain. The price is whatever the compounder and the program that resells it decide.
That is the main reason the weight management category shows the widest price spread of anything in consumer telehealth. Compounded semaglutide and tirzepatide are not FDA-approved, and the agency does not review those preparations for safety, effectiveness, or manufacturing quality before they are dispensed. A pharmacovigilance analysis of adverse event reports involving compounded GLP-1 receptor agonists has examined the signals arising from that market.
Rival programs price the same way and publish the arithmetic to make their case. A breakdown of Hims weight management pricing kept by one physician-supervised GLP-1 provider sets the bundled figure line by line against its own, and equivalent pages exist from Ro, Henry Meds, Found, and Noom. The structure in those tables holds up better than the conclusions.
| Price type | Who sets it | What it reflects | How much it moves |
|---|---|---|---|
| Manufacturer list price | The drug maker | A published reference, before rebates | Changes on announcement, rarely |
| Net price after rebates | Manufacturer and plan intermediaries | Confidential negotiated terms | Not visible to patients |
| Retail cash price | The dispensing pharmacy | Local competition and pharmacy type | Varies widely between pharmacies |
| Manufacturer self-pay price | The drug maker, direct to patient | A stated cash rate for approved product | Revised periodically |
| Compounded preparation price | The compounder and the reseller | Ingredient cost, volume, and margin | Wide spread across sellers |
| Subscription platform price | The platform | Drug plus clinical review, delivery, and support | Moves with promotions and term length |
Pharmacy variation is measurable, not folklore
Cash prices for the same prescription differ by pharmacy in ways that have been documented directly. A national cross-sectional study found prices varying by retail pharmacy type, and a separate survey of the generics most prescribed by dermatologists found large cash price differences between pharmacies for identical products. Broader analysis of retail prescription costs points to the same conclusion about what drives them.
For a platform this variation is an input, not an outcome. The program contracts with one dispensing pharmacy or a small network and inherits that pharmacy’s economics, then prices the bundle above it. A patient using the platform never sees the underlying figure, which is a fair trade for convenience and a poor basis for assuming the total is competitive.
Dose-based pricing is why one category moves and others do not
Hair loss and skin products are priced per unit of a stable formulation, so the monthly figure rarely moves once treatment starts. Sexual health is priced by tablet count, so the variable is frequency rather than escalation. Both categories sit on molecules that have been generic for years.
Weight management prices by strength on most programs. Treatment starts at a low dose and steps upward over months, and each step can carry a different price. That structure is standard for the approved products as well, where the labeling for Ozempic and Zepbound sets out the escalation schedule, and it is the single biggest reason a first-month figure understates a first-year figure in this category.
Anyone pricing that escalation ahead of time can read it off the sellers’ own pages. HealthRX lists each strength of its GLP-1 medications with the figure attached, Ro and Henry Meds show the equivalent inside a membership, and LillyDirect and NovoCare quote the approved drug on its own. Lining those four up against a single first-month number is what turns a headline price into a year of planning.
Frequently asked questions
Why do two programs quote such different numbers for the same molecule?
Usually because they are not selling the same product. One may supply an approved drug and the other a compounded preparation, which is not FDA-approved and sits under different rules. Where the product genuinely matches, the difference reflects dispensing arrangements, bundled services, and margin rather than any difference in the drug.
Does the manufacturer list price affect what a cash patient pays?
Indirectly at best. List price anchors negotiations that happen inside the insurance system, and cash patients sit outside it. Manufacturer self-pay channels for approved incretin drugs publish their own stated prices well below list, which is a more useful reference point for anyone paying without coverage.
Is the same prescription cheaper at a retail pharmacy?
Frequently, for older generics, and the spread between pharmacies for identical products has been documented as substantial. The comparison is not like for like, since the platform price includes the clinical evaluation that produced the prescription. For long-established molecules, pricing both routes is worth the fifteen minutes it takes.
What changes a subscription price after sign-up?
A dose increase on any program that prices by strength, the end of an introductory rate, a switch between generic, branded, and compounded product, and a change of billing term. Sellers also revise standing rates. The order page and the billing confirmation are the only current record of what applies.
Sources
- Variation in Prescription Drug Prices by Retail Pharmacy Type: A National Cross-sectional Study. https://pubmed.ncbi.nlm.nih.gov/31569218/
- Trends and determinants of retail prescription drug costs. https://pubmed.ncbi.nlm.nih.gov/35211965/
- Variation in cash price of the generic medications most prescribed by dermatologists in pharmacies across the United States. https://pubmed.ncbi.nlm.nih.gov/27241622/
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system. https://pubmed.ncbi.nlm.nih.gov/40285721/
- FDA, Human Drug Compounding Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- FDA, FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, Generic Drug Facts. https://www.fda.gov/drugs/generic-drugs/generic-drug-facts
- DailyMed, Ozempic prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=OZEMPIC
- DailyMed, Zepbound prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
